Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Receivables: 2023-2025

Historic Receivables for CG Oncology (CGON) over the last 2 years, with Sep 2025 value amounting to $515,000.

  • CG Oncology's Receivables rose 275.91% to $515,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 176.42%. This contributed to the annual value of $92,000 for FY2023, which is N/A change from last year.
  • CG Oncology's Receivables amounted to $515,000 in Q3 2025, which was down 8.36% from $562,000 recorded in Q2 2025.
  • Over the past 5 years, CG Oncology's Receivables peaked at $562,000 during Q2 2025, and registered a low of $92,000 during Q4 2023.
  • Moreover, its 3-year median value for Receivables was $182,000 (2024), whereas its average is $283,714.
  • Data for CG Oncology's Receivables shows a peak YoY skyrocketed of 275.91% (in 2025) over the last 5 years.
  • CG Oncology's Receivables (Quarterly) stood at $92,000 in 2023, then reached $137,000 in 2024, then spiked by 275.91% to $515,000 in 2025.
  • Its last three reported values are $515,000 in Q3 2025, $562,000 for Q2 2025, and $345,000 during Q1 2025.